share_log

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $28

Benzinga ·  Jan 2 13:21

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $34 to $28.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment